Literature DB >> 12552546

Widespread regional myocardial transfection by plasmid encoding Del-1 following retrograde coronary venous delivery.

Dongming Hou1, Fiona Maclaughlin, Mary Thiesse, Vipul R Panchal, Bas C A M Bekkers, Elizabeth A Wilson, Pamela I Rogers, Michael C Coleman, Keith L March.   

Abstract

This study quantifies myocardial transfection following percutaneous retrograde coronary venous delivery (RCVD) of a plasmid encoding human Del-1. RCVD of Del-1, GFP plasmid, or marker dye was conducted in 14 pigs. After selective cannulation of a coronary vein, a delivery site was confirmed by contrast injection and myocardial blush. Ten milliliters of plasmid hDel-1 or GFP was administered. Animals were euthanized 3 and 7 days post-RCVD. hDel-1 gene expression was evaluated by quantitative RT-PCR. An average myocardial expression of 4.5 x 10(5) copies hDel-1/microg total RNA was observed within the approximately 5 x 5 cm(2) target tissue of the left ventricle. GFP expression was detected by fluorescent microscopy. hDel-1 protein expression was confirmed by immunohistochemistry. Regionalized myocardial expression was found in all pigs. hDel-1 RNA was not found in distant tissues except in the three pigs with prominent venovenous washout (PVW). These levels were 3 to 4 log unites lower than those found in myocardium. Single retrograde coronary venous administration resulted in efficient regional myocyte transfection of hDel-1 and GFP. This method may be useful and clinically feasible for myocardial angiogenesis therapy. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12552546     DOI: 10.1002/ccd.10417

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  8 in total

Review 1.  Cardiac gene therapy: optimization of gene delivery techniques in vivo.

Authors:  Michael G Katz; JaBaris D Swain; Jennifer D White; David Low; Hansell Stedman; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

2.  Potential of gene therapy as a treatment for heart failure.

Authors:  Roger J Hajjar
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

Review 3.  Myocardial gene transfer: routes and devices for regulation of transgene expression by modulation of cellular permeability.

Authors:  Michael G Katz; Anthony S Fargnoli; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2013-04-01       Impact factor: 5.695

Review 4.  Gene therapy for heart failure.

Authors:  Lisa Tilemann; Kiyotake Ishikawa; Thomas Weber; Roger J Hajjar
Journal:  Circ Res       Date:  2012-03-02       Impact factor: 17.367

Review 5.  Current strategies for myocardial gene delivery.

Authors:  Michael G Katz; JaBaris D Swain; Catherine E Tomasulo; Marina Sumaroka; Anthony Fargnoli; Charles R Bridges
Journal:  J Mol Cell Cardiol       Date:  2010-09-15       Impact factor: 5.000

6.  Transvenous intramyocardial cellular delivery increases retention in comparison to intracoronary delivery in a porcine model of acute myocardial infarction.

Authors:  Jon C George; Jonathan Goldberg; Matthew Joseph; Nasreen Abdulhameed; Joshua Crist; Hiranmoy Das; Vincent J Pompili
Journal:  J Interv Cardiol       Date:  2008-10       Impact factor: 2.279

Review 7.  Gene therapy for heart failure: where do we stand?

Authors:  Charbel Naim; Armen Yerevanian; Roger J Hajjar
Journal:  Curr Cardiol Rep       Date:  2013-02       Impact factor: 2.931

8.  A designed zinc-finger transcriptional repressor of phospholamban improves function of the failing heart.

Authors:  H Steve Zhang; Dingang Liu; Yan Huang; Stefan Schmidt; Reed Hickey; Dmitry Guschin; Haili Su; Ion S Jovin; Mike Kunis; Sarah Hinkley; Yuxin Liang; Linda Hinh; S Kaye Spratt; Casey C Case; Edward J Rebar; Barbara E Ehrlich; Barbara Ehrlich; Philip D Gregory; Frank J Giordano
Journal:  Mol Ther       Date:  2012-07-24       Impact factor: 11.454

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.